Gilead Sciences is a leader in developing innovative oral medicines targeting PI3K Delta with a focus on B-cell malignancies, including NHL and CLL. The compact design of the full handout (not shown), its concise graphics, and revealing biomedical visualizations serve as a means for the Director of PI3K Clinical Development to share these findings with investors as well as serving as an attention getting leave-behind. Initial pencil sketch with final composite in Illustrator and Photoshop.
Keywords: Color, Design, Information Graphics, Line with Color, Advertising / Marketing, Education, Publishing, Allergy / Immunology, Biotechnology, Cell biology / Histology, Molecular Biology, Pharmacology
© 2011, Gilead Science